Purpose: We aimed to investigate the efficacy of 0.25 mg dose of palonosetron and granisetron in triplet antiemetic prophylaxis in breast cancer patients receiving HEC.
Methods: Patients with nonmetastatic breast cancer who received HEC [doxorubicin or epirubicin plus cyclophosphamide (AC/EC)] were enrolled in the study. The prophylactic triplet antiemetic regimens were used according to the doctor's preference during the first cycle of HEC as intravenous dexamethasone and palonosetron 0.25 mg or granisetron 3 mg on day 1 as well as oral aprepitant (125 mg on day 1 and 80 mg on days 2 and 3).The primary endpoint was complete response rate (CR) on acute and delayed chemotherapy-induced nausea and vomiting (CINV), separately.
Results: A total of 118 female patients were included in the study. Patients received AC (83%), EC (3%), and dose-dense AC (14%) as adjuvant (88%) or neoadjuvant (12%). The majority of patients received palonosetron (59%) containing antiemetic treatment. The CR rate on acute and delayed vomiting was very high and not statistically different in both of the arms (acute 87% vs. 96%, p = 0.089; delayed 90% vs. 92%, p = 0.489), respectively. Nevertheless, the CR rate on either acute or delayed nausea was lower than vomiting (acute 51% vs. 51%; delayed 38% vs. 29%, p = 0.203; respectively).
Conclusions: This is the second study that compared a 0.25 mg dose of palonosetron with first-generation setron in triplet antiemetic prophylaxis in cancer patients receiving HEC. We could not find meaningful statistical differences between two arms, regarding CR rate on acute and delayed CINV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00280-019-03831-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the Efficacy of a Triplet Antiemetic Regimen in Patients with Esophageal Cancer and Diabetes Mellitus Treated with Cisplatin-Based Chemotherapy: A Retrospective Study.
Oncology
December 2024
Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Introduction: Cisplatin-based highly emetogenic chemotherapy is recommended in combination with neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3-receptor antagonist (5HT3RA), dexamethasone (DEX), and olanzapine. However, olanzapine is contraindicated in patients with preexisting diabetes mellitus (DM). This study compared the efficacy of a triplet antiemetic regimen (NK1RA, 5HT3RA, and DEX) in patients with and without preexisting DM treated with cisplatin-based chemotherapy.
View Article and Find Full Text PDFTransplant in myeloma: who, when, and why?
Hematology Am Soc Hematol Educ Program
December 2024
Hematology Department, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse-Oncopole CHU Toulouse, Toulouse, France.
High-dose melphalan supported by autologous transplantation has been the standard of care for eligible patients with newly diagnosed multiple myeloma for nearly 30 years. Several randomized clinical trials have reaffirmed the strong position of transplant in the era of triplets combining proteasome inhibitors, immunomodulatory drugs, and dexamethasone. Although quadruplets are becoming the standard in transplantation programs, no data are currently available on the need for a transplant with new regimens incorporating anti-CD38 monoclonal antibodies.
View Article and Find Full Text PDFHealth care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States.
J Manag Care Spec Pharm
December 2024
Takeda Development Center Americas, Inc., Lexington, MA.
Background: Available treatments for relapsed/refractory multiple myeloma (RRMM) include multiclass triplet regimens such as lenalidomide and dexamethasone (Rd backbone) plus ixazomib (proteasome inhibitor [PI]; I) or daratumumab (monoclonal antibody; D). Although prior real-world studies compared PI-Rd triplets, this research extends those findings by comparing health care costs of a PI-based and a monoclonal antibody-based triplet, IRd and DRd, in patients with RRMM in the United States.
Objective: To describe and compare all-cause and MM-related health care costs in patients with RRMM treated with IRd vs DRd.
Clinical benefits of adding olanzapine to 5-HT receptor antagonist, NK receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
January 2025
Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara‑Cho, Sakyo-ku, Shogoin, Kyoto, 606‑8507, Japan.
Article Synopsis
- Olanzapine is an atypical antipsychotic that helps prevent nausea and vomiting, particularly after highly emetogenic chemotherapy (HEC), but it can cause side effects like hyperglycemia and drowsiness.
- A systematic review and meta-analysis assessed the effectiveness of olanzapine combined with standard triplet antiemetic therapy compared to triplet therapy alone, focusing on outcomes like nausea control and adverse effects.
- Results showed that adding olanzapine significantly improved nausea and vomiting prevention in both acute and delayed phases with minimal adverse effects, indicating it can be beneficial for patients undergoing HEC.
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).
Sci Rep
November 2024
Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8002, Japan.
Article Synopsis
- Dexamethasone, commonly used to prevent nausea from chemotherapy, has side effects that prompt the search for alternatives without it.
- This study tested the efficacy and safety of palonosetron, aprepitant, and olanzapine in chemotherapy-naïve breast cancer patients, assessing their effectiveness in controlling nausea and vomiting.
- Results showed low total control rates (17.1%) for antiemetic therapies excluding dexamethasone, though olanzapine could be a viable replacement for patients unable to use dexamethasone.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!